Literature DB >> 15339680

Heterogeneity of BCL6 rearrangements in nodular lymphocyte predominant Hodgkin's lymphoma.

Iwona Wlodarska1, Michel Stul, Chris De Wolf-Peeters, Anne Hagemeijer.   

Abstract

BACKGROUND AND OBJECTIVES: Nodular lymphocyte-predominant Hodgkin's lymphoma (NLPHL) showed recurrent rearrangement of the BCL6 which is gene detected in 48% of cases analyzed by interphase-fluorescent in situ hybridization (FISH). These findings point to a critical role for BCL6 in the development of this distinct Hodgkin's lymphoma. We present our results of metaphase-FISH analyses aimed at identifying and characterizing BCL6-related chromosomal translocations in NLPHL. DESIGN AND METHODS: Four NLPHL cases with available metaphase spreads obtained either at the time of diagnosis or during progression to diffuse large B-cell lymphoma (DLBCL) were collected. Extensive metaphase-FISH analysis was performed to identify the affected partner chromosomes and reciprocal breakpoints.
RESULTS: Each of the analyzed NLPHL cases showed a different type of BCL6 rearrangement that included the t(3;22)(q27;q11) targeting immunoglobulin (IG) alpha chain locus, complex t(3;7;3;1) involving the 7p12/Ikaros gene region, t(3;9)(q27;p13) affecting an unknown gene in vicinity of PAX5, and t(3;4)(q27;q32) showing the alternative 3q27 breakpoint outside BCL6 and possibly, an internal deletion of BCL6. Retrospective interphase-FISH analysis of 2 cases with subsequent DLBCL showed the same type of BCL6 translocation as in NLPHL samples. INTERPRETATION AND
CONCLUSIONS: The spectrum of BCL6 aberrations targeting IG as well as non-IG loci in NLPHL is similar to that found in DLBCL. These findings further support the hypothesis of a germinal center B-cell-derived origin of NLPHL and of a relationship between these two lymphoma entities. This latter issue is additionally illustrated in two NLPHL patients who subsequently developed DLBCL and showed the same type of BCL6 rearrangements in both tumors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15339680

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  7 in total

Review 1.  A Novel Non-Immunoglobulin (non-Ig)/BCL6 Translocation in Diffuse Large B-Cell Lymphoma Involving Chromosome 10q11.21 Loci and Review on Clinical Consequences of BCL6 Rearrangements.

Authors:  Marie Jarosova; Eva Kriegova; Petra Schneiderova; Regina Fillerova; Vit Prochazka; Michaela Mikesova; Patrik Flodr; Karel Indrak; Tomas Papajik
Journal:  Pathol Oncol Res       Date:  2015-08-30       Impact factor: 3.201

2.  Molecular cytogenetic analyses of immunoglobulin loci in nodular lymphocyte predominant Hodgkin's lymphoma reveal a recurrent IGH-BCL6 juxtaposition.

Authors:  Christoph Renné; José Ignacio Martín-Subero; Martin-Leo Hansmann; Reiner Siebert
Journal:  J Mol Diagn       Date:  2005-08       Impact factor: 5.568

3.  Coexisting and clonally identical classic hodgkin lymphoma and nodular lymphocyte predominant hodgkin lymphoma.

Authors:  Joo Y Song; Franziska C Eberle; Liqiang Xi; Mark Raffeld; Osama Rahma; Wyndham H Wilson; Kieron Dunleavy; Stefania Pittaluga; Elaine S Jaffe
Journal:  Am J Surg Pathol       Date:  2011-05       Impact factor: 6.394

Review 4.  Diagnosis of Hodgkin lymphoma in the modern era.

Authors:  Hao-Wei Wang; Jayalakshmi P Balakrishna; Stefania Pittaluga; Elaine S Jaffe
Journal:  Br J Haematol       Date:  2018-11-08       Impact factor: 6.998

Review 5.  Is Hodgkin lymphoma just another B-cell lymphoma?

Authors:  Harald Stein; Roshanak Bob
Journal:  Curr Hematol Malig Rep       Date:  2009-07       Impact factor: 3.952

Review 6.  Hodgkin Lymphoma: Biology and Differential Diagnostic Problem.

Authors:  Taishi Takahara; Akira Satou; Toyonori Tsuzuki; Shigeo Nakamura
Journal:  Diagnostics (Basel)       Date:  2022-06-20

Review 7.  Circulating tumor DNA in Hodgkin lymphoma.

Authors:  Maria Maco; Kristyna Kupcova; Vaclav Herman; Iva Ondeckova; Tomas Kozak; Heidi Mocikova; Ondrej Havranek
Journal:  Ann Hematol       Date:  2022-09-08       Impact factor: 4.030

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.